Literature DB >> 16501610

The promyelocytic leukemia protein stimulates SUMO conjugation in yeast.

B B Quimby1, V Yong-Gonzalez, T Anan, A V Strunnikov, M Dasso.   

Abstract

The promyelocytic leukemia gene was first identified through its fusion to the gene encoding the retinoic acid receptor alpha (RARalpha) in acute promyelocytic leukemia (APL) patients. The promyelocytic leukemia gene product (PML) becomes conjugated in vivo to the small ubiquitin-like protein SUMO-1, altering its behavior and capacity to recruit other proteins to PML nuclear bodies (PML-NBs). In the NB4 cell line, which was derived from an APL patient and expresses PML:RARalpha, we observed a retinoic acid-dependent change in the modification of specific proteins by SUMO-1. To dissect the interaction of PML with the SUMO-1 modification pathway, we used the budding yeast Saccharomyces cerevisiae as a model system through expression of PML and human SUMO-1 (hSUMO-1). We found that PML stimulated hSUMO-1 modification in yeast, in a manner that was dependent upon PML's RING-finger domain. PML:RARalpha also stimulated hSUMO-1 conjugation in yeast. Interestingly, however, PML and PML:RARalpha differentially complemented yeast Smt3p conjugation pathway mutants. These findings point toward a potential function of PML and PML:RARalpha as SUMO E3 enzymes or E3 regulators, and suggest that fusion of RARalpha to PML may affect this activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16501610     DOI: 10.1038/sj.onc.1209335

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

Review 1.  PML nuclear bodies.

Authors:  Valérie Lallemand-Breitenbach; Hugues de Thé
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

2.  SUMO E3 ligase activity of TRIM proteins.

Authors:  Y Chu; X Yang
Journal:  Oncogene       Date:  2010-10-25       Impact factor: 9.867

Review 3.  SUMO junction-what's your function? New insights through SUMO-interacting motifs.

Authors:  Oliver Kerscher
Journal:  EMBO Rep       Date:  2007-06       Impact factor: 8.807

4.  KRAB zinc-finger proteins localise to novel KAP1-containing foci that are adjacent to PML nuclear bodies.

Authors:  Stephanie Briers; Catherine Crawford; Wendy A Bickmore; Heidi G Sutherland
Journal:  J Cell Sci       Date:  2009-03-03       Impact factor: 5.285

Review 5.  PML nuclear bodies: assembly and oxidative stress-sensitive sumoylation.

Authors:  Umut Sahin; Hugues de Thé; Valérie Lallemand-Breitenbach
Journal:  Nucleus       Date:  2014       Impact factor: 4.197

6.  Motor neuron impairment mediated by a sumoylated fragment of the glial glutamate transporter EAAT2.

Authors:  Emily Foran; Alexey Bogush; Michael Goffredo; Paola Roncaglia; Stefano Gustincich; Piera Pasinelli; Davide Trotti
Journal:  Glia       Date:  2011-07-18       Impact factor: 7.452

7.  The Human Cytomegalovirus IE1 Protein Antagonizes PML Nuclear Body-Mediated Intrinsic Immunity via the Inhibition of PML De Novo SUMOylation.

Authors:  Eva-Maria Schilling; Myriam Scherer; Nina Reuter; Johannes Schweininger; Yves A Muller; Thomas Stamminger
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

8.  The ND10 Component Promyelocytic Leukemia Protein Acts as an E3 Ligase for SUMOylation of the Major Immediate Early Protein IE1 of Human Cytomegalovirus.

Authors:  Nina Reuter; Eva-Maria Schilling; Myriam Scherer; Regina Müller; Thomas Stamminger
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

Review 9.  Pondering the puzzle of PML (promyelocytic leukemia) nuclear bodies: can we fit the pieces together using an RNA regulon?

Authors:  Katherine L B Borden
Journal:  Biochim Biophys Acta       Date:  2008-06-18

Review 10.  A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics.

Authors:  Ellen Van Damme; Kris Laukens; Thanh Hai Dang; Xaveer Van Ostade
Journal:  Int J Biol Sci       Date:  2010-01-12       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.